

Michael D Staehler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4585616/publications.pdf>

Version: 2024-02-01

135
papers

10,511
citations

76326

40
h-index

32842

100
g-index

136
all docs

136
docs citations

136
times ranked

10783
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU Guidelines on Renal Cell Carcinoma: 2014 Update. <i>European Urology</i> , 2015, 67, 913-924.	1.9	2,445
2	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	27.0	1,648
3	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. <i>European Urology</i> , 2019, 75, 799-810.	1.9	1,022
4	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 393, 2404-2415.	13.7	778
5	Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>European Urology</i> , 2016, 69, 660-673.	1.9	412
6	Local treatments for metastases of renal cell carcinoma: a systematic review. <i>Lancet Oncology, The</i> , 2014, 15, e549-e561.	10.7	265
7	Single-Phase Dual-Energy CT Allows for Characterization of Renal Masses as Benign or Malignant. <i>Investigative Radiology</i> , 2010, 45, 399-405.	6.2	195
8	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2019, 76, 151-156.	1.9	190
9	Contemporary Management of Small Renal Masses. <i>European Urology</i> , 2011, 60, 501-515.	1.9	164
10	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	1.6	164
11	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2018, 73, 311-315.	1.9	138
12	Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). <i>Cancer</i> , 2018, 124, 934-942.	4.1	125
13	A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 426-436.	1.9	123
14	Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. <i>World Journal of Urology</i> , 2010, 28, 543-547.	2.2	122
15	Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 455-460.	1.6	104
16	Technical description, phantom accuracy, and clinical feasibility for fiducial-free frameless real-time image-guided spinal radiosurgery. <i>Journal of Neurosurgery: Spine</i> , 2006, 5, 303-312.	1.7	101
17	Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. <i>BJU International</i> , 2011, 108, 673-678.	2.5	101
18	Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. <i>American Journal of Surgery</i> , 2011, 202, 158-167.	1.8	93

#	ARTICLE	IF	CITATIONS
19	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>European Urology Focus</i> , 2019, 5, 958-969.	3.1	86
20	Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. <i>European Urology</i> , 2016, 69, 4-6.	1.9	85
21	Single Fraction Radiosurgery for the Treatment of Renal Tumors. <i>Journal of Urology</i> , 2015, 193, 771-775.	0.4	84
22	Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. <i>European Urology</i> , 2016, 70, 265-280.	1.9	81
23	Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 805-809.	1.9	80
24	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 141-149.	5.4	73
25	Laser Therapy for Upper Urinary Tract Transitional Cell Carcinoma: Indications and Management. <i>European Urology</i> , 2009, 56, 65-71.	1.9	70
26	Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 719-722.	1.9	69
27	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019, 5, 857-866.	3.1	67
28	S-TRAC trial: Sensitivity analyses of disease-free survival (DFS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-633.	1.6	65
29	Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. <i>European Urology Oncology</i> , 2020, 3, 57-72.	5.4	62
30	An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 511-521.	3.8	61
31	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	1.9	60
32	Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 339.e9-339.e15.	1.6	57
33	Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT correlation with microvascular density. <i>European Radiology</i> , 2020, 30, 1-10.	4.5	57
34	Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 637-645.	2.4	56
35	Tumor Infiltrated Hilar and Mediastinal Lymph Nodes are an Independent Prognostic Factor for Decreased Survival After Pulmonary Metastasectomy in Patients With Renal Cell Carcinoma. <i>Journal of Urology</i> , 2010, 184, 1888-1894.	0.4	52
36	Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?. <i>European Urology Focus</i> , 2020, 6, 1097-1103.	3.1	52

#	ARTICLE	IF	CITATIONS
37	Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer. <i>European Radiology</i> , 2017, 27, 2532-2537.	4.5	48
38	Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e209-e215.	1.9	46
39	CyberKnife Radiosurgery for Malignant Spinal Tumors. <i>Spine</i> , 2008, 33, 2929-2934.	2.0	45
40	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 433-452.	5.4	43
41	Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e345-e355.	1.9	39
42	Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 290-293.	1.6	36
43	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor—Targeted Therapy. <i>European Urology</i> , 2016, 70, 705-706.	1.9	34
44	Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. <i>Acta Ophthalmologica</i> , 2008, 86, 456-458.	1.1	33
45	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 22-41.	5.4	33
46	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. <i>International Journal of Urology</i> , 2019, 26, 532-542.	1.0	31
47	Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation. <i>European Journal of Medical Research</i> , 2010, 15, 287.	2.2	30
48	Systematic Review of the Management of Local Kidney Cancer Relapse. <i>European Urology Oncology</i> , 2018, 1, 512-523.	5.4	30
49	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019, 75, 261-264.	1.9	30
50	Carcinoma of the Collecting Ducts of Bellini of the Kidney: Adjuvant Chemotherapy Followed by Multikinase Inhibition with Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 58-61.	1.9	29
51	Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 139-144.	1.6	27
52	SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 393-393.	1.6	26
53	Combined Diffusion-Weighted, Blood Oxygen Level—Dependent, and Dynamic Contrast-Enhanced MRI for Characterization and Differentiation of Renal Cell Carcinoma. <i>Academic Radiology</i> , 2013, 20, 685-693.	2.5	25
54	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor—targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020, 3, 168-173.	5.4	25

#	ARTICLE	IF	CITATIONS
55	Renal surgery in the elderly: morbidity in patients aged >75 years in a contemporary series. <i>BJU International</i> , 2008, 102, 684-687.	2.5	24
56	The role of metastasectomy in metastatic renal cell carcinoma. <i>Nature Reviews Urology</i> , 2011, 8, 180-181.	3.8	20
57	Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. <i>BMC Cancer</i> , 2015, 15, 303.	2.6	20
58	Outcome Assessment of Patients With Metastatic Renal Cell Carcinoma Under Systemic Therapy Using Artificial Neural Networks. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 37-42.	1.9	18
59	Nephron Sparing Surgery Associated With Better Survival Than Radical Nephrectomy in Patients Treated for Unforeseen Benign Renal Tumors. <i>Urology</i> , 2016, 93, 117-123.	1.0	17
60	Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1101-e1115.	1.9	16
61	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2020, 16, e1264-e1271.	2.9	16
62	The growth rate of large renal masses opposes active surveillance. <i>BJU International</i> , 2010, 105, 928-931.	2.5	15
63	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	1.0	15
64	How the COVID-19 Pandemic Affects Sexual Behavior of Hetero-, Homo-, and Bisexual Males in Germany. <i>Sexual Medicine</i> , 2021, 9, 100380-100380.	1.6	15
65	⁶⁸ Ga-EMP-100 PET/CT – a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma – first in-human biodistribution and imaging results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1711-1720.	6.4	15
66	Therapeutic approaches in metastatic renal cell carcinoma. <i>BJU International</i> , 2005, 95, 1153-1161.	2.5	14
67	Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study. <i>Onkologie</i> , 2013, 36, 95-100.	0.8	14
68	Distress in patients with renal cell carcinoma: a curious gap in knowledge. <i>BJU International</i> , 2019, 123, 208-209.	2.5	14
69	Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI – CEUS) in Oncology. <i>Cancers</i> , 2020, 12, 2821.	3.7	14
70	Long-term outcomes after resection of Stage IV cavoatrial tumour extension using deep hypothermic circulatory arrest. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 892-897.	1.4	13
71	Patients' Perspective on Digital Technologies in Advanced Genitourinary Cancers. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 76-82.e6.	1.9	12
72	A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 11.	2.8	11
74	COVID-19 and financial toxicity in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 2559-2565.	2.2	11
75	Profile of temsirolimus in the treatment of advanced renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2010, 3, 191.	2.0	10
76	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	2.2	10
77	Contrast-Enhanced Ultrasound (CEUS) for Follow-Up of Bosniak 2F Complex Renal Cystic Lesions—A 12-Year Retrospective Study in a Specialized European Center. <i>Cancers</i> , 2020, 12, 2170.	3.7	10
78	Contrast-Enhanced Ultrasound (CEUS) for the Evaluation of Bosniak III Complex Renal Cystic Lesions—A 10-Year Specialized European Single-Center Experience with Histopathological Validation. <i>Medicina (Lithuania)</i> , 2020, 56, 692.	2.0	10
79	Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1355-1362.	3.1	9
80	Fournier's Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature. <i>Cureus</i> , 2019, 11, e5778.	0.5	9
81	Emphysematous pyelonephritis: Case report and literature overview. <i>Urologia</i> , 2018, 85, 123-126.	0.7	8
82	Optimized management of urolithiasis by coloured stent-stone contrast using dual-energy computed tomography (DECT). <i>BMC Urology</i> , 2019, 19, 29.	1.4	8
83	Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. <i>European Journal of Medical Research</i> , 2008, 13, 531-5.	2.2	8
84	Everolimus after failure of one prior VEGF -targeted therapy in metastatic renal cell carcinoma: Final results of the MARC -2 trial. <i>International Journal of Cancer</i> , 2021, 148, 1685-1694.	5.1	7
85	Mapping Telemedicine in German Private Practice Urological Care: Implications for Transitioning beyond the COVID-19 Pandemic. <i>Urologia Internationalis</i> , 2021, 105, 650-656.	1.3	7
86	Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma. <i>European Urology</i> , 2018, 74, 842-843.	1.9	6
87	Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry. <i>International Journal of Cancer</i> , 2020, 146, 1307-1315.	5.1	6
88	Patient preferences and expectations of systemic therapy in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5083-5083.	1.6	6
89	First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. <i>International Journal of Cancer</i> , 2021, 148, 950-960.	5.1	5
90	New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?. <i>European Urology</i> , 2018, 73, 1-3.	1.9	4

#	ARTICLE	IF	CITATIONS
91	Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 654-654.	1.6	4
92	Partial Nephrectomy in pT3a Tumors Less Than 7 cm in Diameter Has a Superior Overall Survival Compared to Radical Nephrectomy. Cureus, 2019, 11, e5781.	0.5	4
93	Dynamics of urinary and respiratory shedding of Severe acute respiratory syndrome virus 2 (SARS-CoV-2) RNA excludes urine as a relevant source of viral transmission. Infection, 2022, 50, 635-642.	4.7	4
94	Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy. Urologia Internationalis, 2010, 84, 119-121.	1.3	3
95	Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma. Urologia Internationalis, 2018, 101, 409-416.	1.3	3
96	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. European Urology, 2018, 74, 849-851.	1.9	3
97	Metastatic papillary renal cell carcinoma in the era of targeted therapy â€” a retrospective study from three European academic centres. Acta Oncologica, 2019, 58, 306-312.	1.8	3
98	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanioâ€™s Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002 . [Epub ahead of print]. European Urology Focus, 2021, 7, 404-405.	3.1	3
99	Structured Reporting in the Characterization of Renal Cysts by Contrast-Enhanced Ultrasound (CEUS) Using the Bosniak Classification Systemâ€”Improvement of Report Quality and Interdisciplinary Communication. Diagnostics, 2021, 11, 313.	2.6	3
100	Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.. Journal of Clinical Oncology, 2014, 32, 469-469.	1.6	3
101	Real-World Results from One Year of Therapy with Tivozanib. Kidney Cancer, 2019, 3, 235-239.	0.4	2
102	Safety and Efficacy of Robotic Radiosurgery for Visceral and Lymph Node Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. Cancers, 2021, 13, 680.	3.7	2
103	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 2021, 13, 2594.	3.7	2
104	Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis.. Journal of Clinical Oncology, 2018, 36, 637-637.	1.6	2
105	Patients perspectives on adjuvant therapy in renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 644-644.	1.6	2
106	Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma. Cureus, 2019, 11, e4244.	0.5	2
107	Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.. Journal of Clinical Oncology, 2019, 37, 636-636.	1.6	2
108	Propensity Score-Matched Analysis of Single Fraction Robotic Radiosurgery Versus Open Partial Nephrectomy in Renal Cell Carcinoma: Oncological Outcomes. Cureus, 2022, 14, e21623.	0.5	2

#	ARTICLE	IF	CITATIONS
109	Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sunitinib Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. <i>Eur Urol</i> 2008;53:845-848. <i>European Urology</i> , 2008, 54, 950-951.	1.9	1
110	Editorial Comment on: Identification of Stanniocalcin 2 as Prognostic Marker in Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 678.	1.9	1
111	A Return to the Days of Radical Nephrectomy as the "Gold Standard" for Localized Renal Cell Carcinoma? Not So Fast. <i>European Urology</i> , 2019, 75, 546-547.	1.9	1
112	Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on 18F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression. <i>Diagnostics</i> , 2021, 11, 423.	2.6	1
113	Stereotactic Radiotherapy for Oligoprogressive Disease: A New Frontier in Kidney Cancer. <i>European Urology</i> , 2021, 80, 701-702.	1.9	1
114	Survival of patients with papillary type II renal cell carcinoma treated with tyrosine-kinase inhibitors: A comparison with clear cell histologies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 511-511.	1.6	1
115	Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4562-4562.	1.6	1
116	Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4571-4571.	1.6	1
117	Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 576-576.	1.6	1
118	Comparison of efficacy and safety of checkpoint inhibitors in patients with genitourinary cancers aged below and above 75 years.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16101-e16101.	1.6	1
119	Patient perspectives on cytoreductive nephrectomy after CARMENA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 658-658.	1.6	1
120	Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 589-589.	1.6	1
121	Frustration and distress during treatment for advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 47-47.	1.6	1
122	Heterogeneity of PD-L1 expression between primary and metastatic bladder cancer tumors and therapeutic implications between the immune cell score and combined positivity score.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17041-e17041.	1.6	1
123	Image-Guided Robotic Radiosurgery for the Treatment of Lung Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. <i>Cancers</i> , 2022, 14, 356.	3.7	1
124	Editorial Comment on: Associations of Single Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Gene with the Characteristics and Prognosis of Renal Cell Carcinomas. <i>European Urology</i> , 2007, 52, 1155.	1.9	0
125	Author Reply. <i>Urology</i> , 2016, 93, 122-123.	1.0	0
126	Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 13.e1-13.e8.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Polyethylene glycol-coated collagen patch (hemopatch®) in open partial nephrectomy. World Journal of Urology, 2022, 40, 127-132.	2.2	0
128	Contribution of interleukin-22, a T cell secreted cytokine, to renal cell carcinoma progression and association with poor outcome in RCC patients.. Journal of Clinical Oncology, 2016, 34, 4569-4569.	1.6	0
129	Development of a conversation aid tool for patients with localized renal cell carcinoma at high risk of recurrence.. Journal of Clinical Oncology, 2018, 36, 608-608.	1.6	0
130	Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.. Journal of Clinical Oncology, 2018, 36, 4565-4565.	1.6	0
131	Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/KCCure survey.. Journal of Clinical Oncology, 2018, 36, 4570-4570.	1.6	0
132	Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.. Journal of Clinical Oncology, 2020, 38, 5084-5084.	1.6	0
133	Fear of cancer recurrence among patients and survivors diagnosed with localized renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 649-649.	1.6	0
134	CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.. Journal of Clinical Oncology, 2020, 38, TPS770-TPS770.	1.6	0
135	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. Acta Oncologica, 2022, 61, 52-57.	1.8	0